Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine
- PMID: 761446
- DOI: 10.1002/cpt1979253358
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine
Abstract
We propose a model of drug pharmacodynamic response that when integrated with a pharmacokinetic model allows characterization of the temporal aspects of pharmacodynamics as well as the time-independent sensitivity component. The total model can accommodate extremes of effect. It allows fitting of simultaneous plasma concentration (Cp) and effect data from the initial distribution phase of drug administration, or from any non-equilibrium phase. The model postulates a hypothetical effect compartment, the dynamics of which are adjusted to reflect the temporal dynamics of drug effect. The effect compartment is modeled as an additional compartment linked to the plasma compartment by a first-order process, but whose exponential does not enter into the pharmacokinetic solution for the mass of drug in the body. The hypothetical amount of drug in the effect compartment is then related to the observed effect by the Hill equation, a nonlinear sigmoid form. Nonlinear least-squares data fitting is used for parameter estimation. The model is demonstrated on two different sets of Cp and effect data for the drug d-tubocurarine (dTC). In 7 normal subjects, the (mean +/- SD) rate constant for equilibration of dTC effect (paralysis) and Cp is 0.13 +/- 0.04 min-1 and the (mean +/- SD) steady-state Cp required to produce 50% paralysis is 0.37 +/- 0.05 microgram/ml.
Similar articles
-
Pharmacokinetics of tubocurarine administered by combined i.v. bolus and infusion.Br J Anaesth. 1980 Sep;52(9):893-9. doi: 10.1093/bja/52.9.893. Br J Anaesth. 1980. PMID: 7437228
-
Relationship between gallamine plasma concentration and neuromuscular paralysis in surgical patients.J Clin Pharmacol. 1983 May-Jun;23(5-6):243-51. doi: 10.1002/j.1552-4604.1983.tb02731.x. J Clin Pharmacol. 1983. PMID: 6875023
-
Studies in man with a constant-rate infusion of tubocurarine.Anaesth Intensive Care. 1979 Aug;7(3):209-14. doi: 10.1177/0310057X7900700301. Anaesth Intensive Care. 1979. PMID: 495928
-
Pharmacokinetic and pharmacodynamic modeling in vivo.Crit Rev Bioeng. 1981;5(4):273-322. Crit Rev Bioeng. 1981. PMID: 7023829 Review.
-
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13. Int J Clin Pharmacol Ther. 1997. PMID: 9352388 Review.
Cited by
-
Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects.Eur J Clin Pharmacol. 2012 Nov;68(11):1473-81. doi: 10.1007/s00228-012-1286-6. Epub 2012 Apr 21. Eur J Clin Pharmacol. 2012. PMID: 22527350 Clinical Trial.
-
Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.AAPS J. 2015 Sep;17(5):1157-67. doi: 10.1208/s12248-015-9779-8. Epub 2015 May 15. AAPS J. 2015. PMID: 25975616 Free PMC article.
-
Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow.Eur J Clin Pharmacol. 1992;42(6):655-61. doi: 10.1007/BF00265932. Eur J Clin Pharmacol. 1992. PMID: 1623908 Clinical Trial.
-
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):347-63. doi: 10.1007/s10928-010-9164-2. Epub 2010 Jul 23. J Pharmacokinet Pharmacodyn. 2010. PMID: 20652729 Free PMC article. Clinical Trial.
-
Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):57-85. doi: 10.1007/s10928-006-9035-z. Epub 2006 Oct 19. J Pharmacokinet Pharmacodyn. 2007. PMID: 17051439
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous